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Abstract
Bone tissue has an astonishing self-healing capacity yet only for non-critical size defects (<6 mm) and clinical intervention is
needed for critical-size defects and beyond that along with non-union bone fractures and bone defects larger than critical size
represent a major healthcare problem. Autografts are, still, being used as preferred to treat large bone defects. Mostly, due to
the presence of living differentiated and progenitor cells, its osteogenic, osteoinductive and osteoconductive properties that
allow osteogenesis, vascularization, and provide structural support. Bone tissue engineering strategies have been proposed to
overcome the limited supply of grafts. Complete and successful bone regeneration can be influenced by several factors
namely: the age of the patient, health, gender and is expected that the ideal scaffold for bone regeneration combines factors
such as bioactivity and osteoinductivity. The commercially available products have as their main function the replacement of
bone. Moreover, scaffolds still present limitations including poor osteointegration and limited vascularization. The
introduction of pores in scaffolds are being used to promote the osteointegration as it allows cell and vessel infiltration.
Moreover, combinations with growth factors or coatings have been explored as they can improve the osteoconductive and
osteoinductive properties of the scaffold. This review focuses on the bone defects treatments and on the research of scaffolds
for bone regeneration. Moreover, it summarizes the latest progress in the development of coatings used in bone tissue
engineering. Despite the interesting advances which include the development of hybrid scaffolds, there are still important
challenges that need to be addressed in order to fasten translation of scaffolds into the clinical scenario. Finally, we must
reflect on the main challenges for bone tissue regeneration. There is a need to achieve a proper mechanical properties to bear
the load of movements; have a scaffolds with a structure that fit the bone anatomy.
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1 Bone tissue biocomposition
Bone is a complex heterogeneous, hierarchically structured
tissue consisting of a mineral phase, hydroxyapatite (Ca10
(PO4)6(OH)2); an organic phase (~90% type I collagen, ~5%
non-collagenous proteins, ~2% lipids by weight); and
contains between 10% and 20% of water [1]. The cellular
components of bone consist of osteogenic precursor cells,
osteoblasts, osteoclasts, osteocytes, and hematopoietic ele-
ments of bone marrow. Osteoblasts are mature, metaboli-
cally active and are involved in the bone formation process
[2–4]. When osteoblasts are engulfed in mineral, they dif-
ferentiate into osteocytes. Osteocytes are mature osteoblasts
trapped within the bone matrix. From each osteocyte, a
network of cytoplasmic processes extends through cylind-
rical canaliculi to blood vessels and other osteocytes
allowing their communication [2, 3]. They are also involved
in adaptive remodeling behavior via cell-to-cell interactions
in response to the local environment. Osteoclasts are mul-
tinucleated which absorbs bone mineral and bone matrix
and are controlled by hormonal and cellular mechanisms
[2–4]. Bone is highly vascularized and, the blood flow is
correlated to its metabolic activity. In long bones, one or
two principal diaphyseal nutrient arteries represent the most
important supply of blood and pass obliquely through the
cortical bone [5, 6].
The bones of the skeleton can provide structural support,
allows movement, and provides protection to organs while
also regulates mineral homeostasis and blood pH. There are
four types of bone based on the shape: long bones, short
bones, flat bones, and irregular bones. The long bones are
composed of diaphysis; metaphysis and epiphyses. The
diaphysis is composed mostly by cortical bone, whereas the
metaphysis and epiphysis are composed of trabecular
meshwork bone surround by a thin layer of dense cortical
bone [7, 8]. There are three types of bone based on their
anatomical shape and composition: woven bone, cortical
bone, and cancellous bone. Woven bone is found during
embryonic development, during fracture healing (callus
formation), and in some pathologic states such as hyper-
parathyroidism and Paget’s disease. Cortical bone is dense
and solid and surrounds the marrow space, whereas trabe-
cular bone is composed of a honeycomb-like network of
trabecular plates and rods interspersed in the bone marrow
compartment [3, 7]. At the macrostructure level, bone can
be distinguished into: trabecular (corresponding to around
20% of the total skeleton), which forms a solid osseous
shell around the bone and consists of dense and parallel,
concentric, lamellar units—the osteons; and cortical bone
(corresponding to around 80% of the total skeleton) which
is remodeled from woven bone. The trabecular bone is
supplied by diffusion from the surrounding bone marrow
and it is surrounded by cortical bone but the thickness and
strength of the cortical shell depend on location [3, 9–11].
Although both types of bone are easily distinguished by
their degree of porosity (trabecular bone is much more
porous) they have other differences such as trabecular bone
being more metabolically active [3, 10].
2 Bone healing process
Mechanical properties of bone depend on age, anatomical
site, and gender. The elastic modulus is the biomechanical
property of bone that draws more interest because of its
critical importance for characterizing bone pathologies and
guiding bone scaffolds design [10, 12]. Mechanical stimu-
lation has a major influence on bone biomechanics prop-
erties. According to Wolff’s law, the mechanical loading
stimulates bone formation [13]. Bone’s viscoelasticity is a
crucial property when referring to bone fracture. The vis-
coelasticity and the strength of bone are properties that are
intimately related to its porosity [14].
Following a bone lesion, the principal factors that influ-
ence the process of bone healing are the availability of blood
supply, the mechanical stability, the size of the defect, the
incidence and severity of surrounding tissue injuries [15].
The process of fracture healing can be considered a regen-
erative process and it is a complex biological process. Bone
heals by either direct or indirect fracture healing. The most
common process is indirect fracture healing and occurs in
three overlapping stages: the early inflammatory stage, the
repair stage, and the late remodeling stage [3]. In the
inflammatory stage, a hematoma develops within the frac-
ture site during the first few hours and days. Inflammatory
cells (macrophages, monocytes, lymphocytes, and poly-
morphonuclear cells) and fibroblasts infiltrate the bone under
prostaglandin mediation. This results in the formation of
granulation tissue, ingrowth of vascular tissue and migration
of mesenchymal cells. As vascular ingrowth progresses, a
collagen matrix is laid down while osteoid is secreted and
subsequently mineralized, which leads to the formation of a
soft callus around the repair site. Eventually, the callus
ossifies by the deposition of osteoblasts forming a bridge of
woven bone between the fracture fragments [3, 16, 17].
Once the fracture has been satisfactorily bridged by callus,
the newly formed bone is restored to its original shape,
structure, and mechanical strength. Any excess callus is
removed and the woven bone is remodeled into the trabe-
cular bone. The fracture healing is completed during this
stage—the remodeling stage. Direct healing is not a natural
process. It requires an anatomical reduction of the fracture
ends and a stable fixation when these requirements are
achieved the direct bone healing can occur [18]. Bone
healing is a major complex process that requires the
recruitment of mesenchymal stem cells (MSCs) and once
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they are recruited, a molecular cascade starts involving
collagen type I and collagen type II matrix production and
the participation of several peptide-signaling molecules.
Growth factor-beta (TGF-β) superfamily members such as
TGF-β2, -β3 and growth differentiation factor 5 (GDF-5) are
also involved in the healing process. Bone morphogenetic
protein (BMP-2), vascular endothelial growth factor (VEGF)
and the involvement of the actions of metalloproteinase are
key factors for the healing cascade [18]. There are numerous
biochemical and cellular factors related to the bone healing
that associated with a biomechanical and anatomical pro-
cess, complete an appropriate regeneration of bone defects.
3 Treatments for bone lesions
To fully understand bone regeneration is important to define
some concepts that are closely related. Osteogenesis,
osteoinduction, osteoconduction, and osteointegration are
the four essential characteristics for the success of the
scaffold. Osteogenesis is the capacity to produce new bone
by the differentiation of osteoblasts. Osteoinduction has
been defined as the process of recruitment, proliferation,
and differentiation of host mesenchymal stem cells into
chondrocytes and osteoblasts. Osteoconduction is the ability
to provide an environment capable of hosting the indigen-
ous mesenchymal stem cells, osteoblasts, and osteoclasts.
The final bonding between the host bone and the scaffold is
called osteointegration [19, 20].
There are numerous approaches to promoting bone tis-
sue regeneration. One of the possible treatment is a sur-
gical procedure with autograft or allograft bone [21, 22].
Autologous bone grafts consist of taking bone from
another part of the patient’s own body and is considered
the clinical “gold standard”. It is the most effective method
for bone regeneration as it promotes bone formation over
its surface by direct bone bonding and induces local stem
cells to differentiate into bone cells without any associated
immune response. It is commonly taken in the form of
trabecular bone from the patient’s iliac crest. Although it
presents a relatively good degree of success, the range of
cases in which it can be used is restricted, mainly due to
the limited amount of the autograft that can be obtained
and due to donor site morbidity [11, 23]. The vascularized
free fibular bone graft is a type of autogenous bone graft
and it was first described in 1975 by Taylor [24]. It is used
in large bone defects, more than 5–6 cm [25]. The
advantage of this method is the availability of bone stock,
a faster union, less resorption of bone and lower fatigue
fracture. This process involves a long surgical procedure
and can increase the morbidity on the donor site. In
addition, there is a demand for further information about
the factors that lead to failure [25, 26].
Allograft, bone is taken from a donor, could be an
alternative to the use of autografts. However, when com-
pared with autograft the rate of graft incorporation within
the bone is lower. Allograft likewise may cause immune
rejection and pathogen transmission from donor to reci-
pient, and although infrequent, infections could occur in the
recipient’s body after the transplantation [11, 27]. In 1957
bovine bone was first introduced [28]. Xenograft bone
substitutes have their origin from a species other than
human, it is similar to autologous bone grafts in that both
are osteoconductive and relatively inexpensive [29]. How-
ever, there may be a transmission of animal diseases.
Recently, the induced membrane technique or Masque-
let technique has been used to treat large bone defects. It is
a two-step procedure: first, radical soft tissue and bone
debridement are undertaken, then a cement spacer of
polymethyl methacrylate (PMMA) is placed at the site of
the bone defect and is stabilized with an external fixator
[30, 31]. The cement spacer prevents fibrous tissue inva-
sion of the defect and induces the surrounding membrane
hat will promote the revascularization of the bone graft
[32, 33]. Secondly, 6–8 weeks later the induced membrane
is carefully incised, the spacer removed and cancellous
bone from the iliac crest is implanted and the membrane
closed with definitive fixation. Although is an interesting
method, there are complications and studies for a better
understanding of the procedure and complications are
necessary [34].
4 Scaffolds for regeneration
4.1 Scaffolds-based tissue engineering
Tissue engineering paradigm has several components: a
scaffold that mimics the tissue that needs to be regenerated;
cells to lay down the ECM; morphogenic signs so cells can
differentiate. Tissue engineering can be applied to all types
of tissues that constitutes human body such as bone tissue
[35, 36], osteochondral [37, 38], cartilage [39, 40], neural
tissue [41, 42]; skeletal tissue [43, 44]; skin [45, 46];
meniscus [47, 48]; or even blood vessels [49]. Bone tissue
engineering strategies aim to achieve bone regeneration
which is required in several clinical conditions including but
not limited to osteoporosis [15, 50], bone infection [15] and
resection of musculoskeletal sarcoma which usually results
in large bone defects [51].
Tissue engineering products for bone treatment can be
divided into two groups: those that stimulate bone regen-
eration and those that provide a permanent solution, as a
substitute for bone [52]. For the treatment of bone defects,
the ideal scaffold should be developed to meet some
important requirements (Table 1).
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Studies that compare the bone regeneration using auto-
graft with materials that can be used as substitutes have been
performed. Bioactive glass (BG) is an interesting biomaterial
especially due to its ability to form a reactive carbonated HA
layer [53]. A prospective randomized study was performed
in 25 patients with benign bone tumors. The patients were
surgically treated with either bioactive glass S53P4 (BG) or
autogenous bone (AB) as bone graft material. It was
observed a significant difference was presented between the
AB and BGs group in how the bone cavities remodeled over
time. The time of disappearance was significantly longer in
the BG. For a more reliable conclusion, the study should
have a longer period of patient analysis [54].
Calcium phosphate types of cement have been developed
in order to be injected as a doughy substance and that
cancan cure over several hours upon implantation. In 1998,
the first injectable biologic cement was approved by the
Food and Drug Administration (FDA). Injectable mineral
types of cement are widely used as a solution to treat bone
defects due to their chemical composition being close to the
mineral component of bone ECM. They have an advantage
over blocks, granules, and pellets, in that a personalized fill
of the defect is possible [19]. In a retrospective chart review,
a direct comparison of autografts, bone cement, and demi-
neralized bone matrix in terms of function and outcomes
was performed. Demineralized bone matrix was the primary
reconstructive material used in six patients. Seventeen
patients had bone cement as the reconstructive material for
cranioplasty; six patients had demineralized bone matrix,
and five patients had bone autografts. It was concluded that
residual defects and revision rates were significantly less
when autograft or bone cement was used [55].
An injectable composite cement of phytic acid-derived
bioactive glass with a high content of BG was recently
developed and tested in vivo in a rabbit femoral condyle
defect. The outcomes revealed that the cement had a better
capacity than the polymethyl methacrylate and calcium
sulfate cement in terms of bone regeneration as well as the
resorption rate observed in a critical-sized rabbit femoral
condyle defect model. This made this cement promising for
the treatment of bone defects as at the 12th week, showed
signals appeared at the edge of the implanted cement,
indicating new bone [56]. A large number of bone-graft
alternatives are currently commercially available for ortho-
pedic use. They vary in composition, mechanism of action
and characteristics. Their composition includes mineral
composites, ceramics, mineral cement, BGs and synthetic
bone substitutes [19, 57]. Table 2 summarizes the current
commercially available products for treating bone lesions.
An important observation on what is being commercialized
is that most of these products’ purpose is to fill the defect
and not to promote bone regeneration. It is expected from
the next generation of products to be multifunctional by
incorporation of growth factors and/or cells.
The biomaterial biocompatibility can be evaluated. In
the design of tissue engineering scaffolds parameters
including surface topography, chemistry, surface energy,
and wettability, pore size, shape, mechanical properties
should be optimized to maximize the bone ingrowth
[58, 59]. Moreover, elasticity, compression or shear stress
can influence cell behavior and even epigenetic status
[60, 61]. Surface characteristics are critical for the suc-
cessful design and medical application of biomaterials as
the surface is the earliest contact with the biological
environment [8, 62].
Surface properties, both chemical and topographical, can
influence cellular adhesion and proliferation as it is involved
in many of biological events occurring after implantation,
which range from protein adhesion to bone remodeling
[11, 63]. Topographies such as random nanofibers normally
can influence cells into spreading and polygonal shapes
which promote the process of osteogenic differentiation [64].
Table 1 Requirements for the
design of scaffolds in bone
tissue engineering
[12, 136, 153, 154]
Features for the success of scaffold Importance of the feature
Biocompatibility Capacity to be in a host tissue without initiate an inflammatory
response
Osteoinductive Able to recruit and differentiate mesenchymal cells
Chemistry Influence cell behavior
Suitable surface topography Influence cellular behavior such as adhesion, proliferation, and
differentiation
3D structure Host of the newly formed tissue
Allows the formation of new tissue in a 3D manner
Mechanical properties Support the defect area
Influence cell behavior
Porosity and pore shape Allows tissue ingrowth, nutrient and oxygen change;
neovascularization and influence cell behavior
Wettability A proper wettability enhances the adhesion of proteins and thus the
cell attachment
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Many studies have shown a relationship between cell
attachment and surface roughness. In a study, three varia-
tions of surface-modified porous titanium and conclude that
the surface treatment improved cell response [65]. It was
observed in a study [66] that cells exhibit protruding filo-
podia in honeycomb-like scaffolds of PCL/nHA which
indicates a proper cell spread. For achieving the adequate
scaffold integration, a surface with roughness is favorable as
it cancan enhance attachment, proliferation, and differ-
entiation of anchorage-dependent bone-forming cells
[62, 63, 67, 68]. Parameters such as wettability and surface
free energy can also influence cell growth as it was
observed in a study [69]. It was concluded that surface free
energy was a critical parameter for cellular adhesion and
proliferation rather than roughness.
The importance of having a porous scaffold in bone
regeneration was shown a study where a porous scaffold of
hydroxyapatite (HA) for BMP-2 delivery was tested using
a rat model [70]. In order to achieve a solid bone regen-
eration in a scaffold, it is necessary a proper vasculariza-
tion. Moreover, cells from the surrounding must be able to
penetrate. Pore size is, thus, an important feature since if
the pores are too small, pore occlusion by the cells will
happen and it is also an important factor for protein
adsorption, cellular migration and osteoconduction
[11, 71]. Pore sizes greater than 300 µm are recommended
for bone ingrowth in comparison with smaller pore size
[67, 72–74]. Fukuda et al. [75] compared the osteoinduc-
tion for different pore sizes, 500 µm, 600 µm, 900 µm, and
1200 µm, in identical environments. In this study, a 500 μm
pore size presented excellent osteoinduction. However, in
another study with different pore sizes [76] including
300 μm, 600 μm, and 900 μm, it was observed significantly
higher fixation ability in 600 μm pore size. An experiment
with scaffolds with pore sizes of 60 μm, 100 μm, 200 μm,
and 600 μm was performed by Prananingrum et al. [71]
after three weeks implanted into rabbit calvaria the scaffold
with 600 μm pore size showed a greater bone ingrowth.
Nevertheless, after 20 weeks the pore size of 100 μm pre-
sented greater bone ingrowth than the other pore sizes. In
that study, they suggested that bone regeneration into
porous scaffolds is pore size-dependent whereas bone
ingrowth was most prominent for the 100 μm sized pores
after 20 weeks in vivo. Porosity and pore size of a scaffold
for bone tissue regeneration are key factors that will
improve biologically allowing bone ingrowth and infiltra-
tion of cells and nutrients. Nevertheless, these features
become conflicting with others as the increase of pore size
the strength of the scaffold decrease which can lead to
failure in vivo.
Today, biomaterials that are used to prepare scaffolds
can be natural or synthetic, degradable or non-degradable.
For example, natural polymers chitin and chitosan or col-
lagen are being used for applications in tissue engineering
[77, 78]. Synthetic polymers such as Polycaprolactone
(PCL), Poly-lactic acid (PLA) or Poly (lactic-co-glycolic)
acid (PLGA) are biodegradable and can be produced with
different features for applications in bone tissue engineer-
ing [79]. Table 3 overviews the advantages and dis-
advantages of the most common materials used in the bone.
Among those, hydrogels possessing hydrated polymer
chains have been gaining much attention as a delivery
system of cells and growth factors for bone tissue engi-
neering applications [80, 81].
Table 2 Commercially available products used to treat bone lesions
Composition Form Product Company Reference
Calcium phosphate Paste Norian SRS Synthes (PA, USA) [57, 155]
50% calcium sulfate, 10% calcium phosphate,
and 40% DBM
Paste PRO-STIM Wright Medical Technology
(TN, USA)
[156]
A mix of calcium hydroxide and iodoform Paste Vitapex Neo Dental Chemical Products
(Tokyo, Japan)
[157]
Silicate substitute calcium phosphate Paste Infuse Medtronic (Minneapolis, USA) [158, 159]
19.5% demineralized bone, 12.5% cancellous
allograft and reverse phase medium (RPM)
Putty or paste OrthoBlast Isotis Orthobiologics (CA, USA) [160]
Porous silicon substituted HA granules Paste/solid ACTIFUSE Baxter International (IL, USA) [158, 161]
DBM/gelatin Gel/paste/solid Optefil Exactech (FL, USA) [162, 163]
Calcium sulfate and DBM Putty Allomatrix Wright Medical Technology
(TN, USA)
[164, 165]
Dibasic calcium phosphate and collagen type I Solid CopiOs Zimmer (IN, USA) [166]











Vitoss Orthovita (PA, USA) [168, 169]
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4.2 Metallic biomaterials
Biodegradable metals like Mg, Zn, Fe, and their alloys
have a potential for load-bearing application and they are
used in clinics for more than a decade [82, 83]. The first use
of Fe to repair the human body was as a dental implant
[84]. Recently, the potential of biodegradable Mg screws
was evaluated for the fixation of vascularized bone graft in
osteonecrosis of the femoral head patients. The of this
study results suggested that the treatment efficacy in terms
of better stabilization of the bone flap as compared with the
conventional [85].
Metallic non-degradable biomaterials are mainly used for
the fabrication of scaffolds for the replacement of hard tissue
such as artificial hip joints, bone plates, and dental implants.
These are attracting a great deal of attention due to their
mechanical properties and corrosion resistance [86–88].
Stainless steel was the first metallic biomaterial used suc-
cessfully as an implant and it is one of the main metallic
materials used amongst with Co-based alloys, Ti and its
alloys [87, 89, 90]. Stainless steel is a popular metal for use
as an acceptable cup (one half of an artificial hip joint)
applications [88, 91]. Stainless steel materials are resistant
to a wide range of corrosive agents due to their high Cr
(Chromium) content which cancan allow the formation of
the strongly adherent, self-healing and corrosion resistant
coating oxide.
Titanium and its alloys are widely used in biomedical
applications due to their excellent mechanical, physical,
biological performance, corrosion resistance, and their
outstanding biocompatibility. Commercially pure Ti (CP
Ti), typically with single-phase alpha microstructure, is
currently used in dental implants while titanium with 6%
aluminum and 4% vanadium, Ti6Al4V, is mostly used in
the orthopedic field. The Al and V alloy elements stabilize
the alpha-beta microstructure and improve the mechanical
properties [92, 93]. The Ti6Al4V is used for their excellent
corrosion resistance and their modulus of elasticity
(113 GPa) that is approximately one-half that of stainless
steel (210 GPa) and Co–Cr alloys (240 GPa) and conse-
quently the stress shielding will be lower [93–96].
Ti-mesh as an alternative treatment for the reconstruction
of critical segmental bone defects was tested [97]. They
observed bone formation on the scaffold surface in a case
example of a 61-year-old woman with non-union of the
femur 16 months after an initial fracture treatment. How-
ever, there was no radiographical evidence of bone growth
through the scaffold mesh. Moreover, not all cases showed
reliable bone defect bridging. In this study, they also
investigate bone regeneration within the mechanobiological
optimized scaffolds in 27 adult sheep. A soft or a stiff
scaffold, filled with the autologous cancellous bone graft
(ABG) was applied within the defect and stabilized with
either common steel locking compression plate (LCP) or a
rigid, custom-made shielding plate. Four groups were tes-
ted: soft+ LCP; stiff+ LCP; soft+ shielding plate and
stiff+ shielding plate. It was observed by the radiographic
follow-up that the soft and stiff scaffolds in combination
with the locking compression plate showed bone formation
Table 3 Advantages and disadvantages of the most common bone




















Rejection of the graft












Availability of healthy grafts
Rejection of the graft more
aggressively































   27 Page 6 of 16 Journal of Materials Science: Materials in Medicine           (2020) 31:27 
patterns similar to those observed in clinical cases. They
observe that a relatively soft, mechanically optimized Ti-
mesh scaffold filled with ABG enhanced regeneration in a
large segmental bone defect in sheep. Machined (MTi) and
alumina-blasted (ABTi) titanium discs were combined with
adipose-derived stem cells (ASCs) to be tested in female
sheep [98]. There was no statistically significant difference
in the formation of new bone generated. This could be due
to the necessity of a longer period of the experiment.
4.3 Ceramic biomaterials
Ceramics are generally defined as inorganic, non-metallic
materials [99]. Bioinert ceramics such as Al, Zr, and several
porous ceramics are the most used in orthopedic devices
[92, 100]. Alumina has a great performance under com-
pression, but is brittle under tension and has been used for
nearly 20 years owing to its low friction and wear coeffi-
cients [92, 100].
Calcium phosphate ceramics have been widely used as
bone substitutes, coatings, types of cement, drug delivery
systems, and tissue engineering scaffolds [101]. Tricalcium
phosphate (TCP) Ca3(PO4)2 is a bioactive and biodegrad-
able ceramic material. TCP implants have been used for two
decades as the synthetic bone void fillers in the orthopedic
and dental application, as it can be observed in Table 2 the
majority of commercial products are composed by calcium
phosphates. BG and its related glass-ceramic biomaterials
are an interesting biodegradable biomaterial used in scaf-
folds for bone regeneration [102]. BG was also used to
reinforce gellan-gum spongy-like hydrogel [53].
Zirconia is one of the ceramic materials with the highest
strength suitable for implants and presents other advantages
like being bioinert, having excellent resistance to corrosion
and wear, high fracture toughness and one of the most is
biocompatible [92, 103, 104]. These favorable mechanical
properties are a consequence of phase transformation
toughening, which increases its crack propagation resis-
tance [99, 105].
4.4 Polymer biomaterials
Biodegradable polymers can be classified into two types:
natural polymers and synthetic polymers. Synthetic poly-
mers have been widely studied especially polyglycolic acid
(PGA), polylactic acid (PLA), polylactide-co-glycolide
(PLGA), poly (d,l-lactic acid), polyethylene glycol (PEG),
and PCL [106]. PGA is very similar to PLA however PLA
exhibits different chemical, physical, and mechanical
properties because of the presence of a pendant methyl
group on the alpha carbon [107]. These polymers can be
used as a drug delivery system [108]. Although they present
characteristics like having good processability and man-
ageability they lack rigidity and stability [109].
Alenezi [110] studied PLGA microspheres within β-TCP
for bone regeneration using a rabbit’s calvaria defect model.
They showed that PLGA was capable of releasing clari-
thromycin increasing the bone regeneration. Natural poly-
mers usually contain specific molecular domains that can
support and guide cells and thus enhance the biological
interaction of the scaffolds with the host tissue [111].
Collagen is the major component of the animal con-
nective tissue and due to its properties has been widely
investigated for biomedical applications. Materials based in
collagen are suitable for both cartilage and bone scaffolds.
Scaffolds composed by: collagen (fibrillar collagen type I,
III, and V from bovine tissue)/hydroxyapatite/β-tricalcium
(CHT) phosphate; CHT plus growth factor cocktail (GFC);
a jellyfish collagen (Rhopilema sp.) matrix; jellyfish col-
lagen (Rhopilema sp.) matrix plus GFC; a collagen powder
(fibrillary collagen type I, III, and V from bovine tissue); a
collagen powder and a collagen powder (fibrillary collagen
type I, III, and V from bovine tissue) plus periodontal
ligament stem cells PDLSC were compared in terms of
bone growth in lower jaw of mini pigs. No additional sig-
nificant enhancement of bone growth was observed upon
the use of GFC or PDLSC [112].
Silk is a natural fibrous polymer consisting of repetitive
protein sequences and due to its characteristics such as
elasticity, biocompatibility and biodegradability have
applicability for bone regeneration [113–115]. Three dif-
ferent scaffolds: alginate, alginate/hydroxyapatite, and algi-
nate/hydroxyapatite/silk fibroin were analyzed in an
experiment [115]. Central calvarial bone defects of forty
Sprague Dawley rats were grafted with alginate, alginate/
hydroxyapatite, or alginate/hydroxyapatite/silk fibroin. Four
weeks after implantation the bone formation was evaluated,
it was observed higher bone formation when the composite
alginate/hydroxyapatite/silk fibroin. Silk and hydroxyapatite
co-operated in a study [116]. The new bone formation was
evaluated for 12 weeks and it was observed higher bone
formation in hydroxyapatite-conjugated silk fibrin scaffold
group. In spite of numerous in vitro and in vivo studies,
there are still no silk based scaffolds in human trials [117].
Alginate is a polysaccharide that has been widely used in
bone tissue engineering. The main application of this bio-
material is as the delivery vehicle was reported in a recent
study where an alginate system was modified to enhance its
cell adhesion, and osteogenic and proangiogenic properties
using gum tragacanth [118]. Alginate also has the potential
to induce osteochondral regeneration. In a study, it was
tested biphasic alginate in six adult sheep and rabbits.
Although, it was shown bone substitution a comparison with
the commercially available product is needed [119].
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Chitosan is a polysaccharide that can be used in many
applications. It exhibits antibacterial activity, along with
antifungal, mucoadhesive, analgesic and hemostatic proper-
ties [120]. A composite scaffold consisting of chitosan (CS),
gelatin (Gel) and platelet gel (PG) was studied [121] in terms
of its healing potential. They observed that their scaffold
showed significantly higher new bone formation, the density
of osseous and cartilaginous tissues, bone volume, and
mechanical performance. It is well accepted that biodegrad-
able polymers are a great biomaterial for bone applications,
however, they present problems such as: the relationship
between degradation rate and mechanical properties; there is
poor degradation rate control; there is a mismatch between
the polymeric biomaterial and the bone. The synthetic
polymers also present some cons as they have poor cell
adhesion and lack of bioactivity; their degradation products
are acidic which can cause inflammation [122].
PEEK is biocompatible, chemically and physically stable,
with excellent mechanical properties and it can be processed
using a variety commercially techniques [123, 124]. More-
over, PEEK is stable at high temperatures with a high
melting point of 334 °C, is insoluble in all conventional
solvents at room temperature, with exception of 98% sul-
furic acid and it remains stable in sterilization processes
[123–125]. The major beneficial property for orthopedics
application its lower Young’s (elastic) modulus (3–4 GPa)
being close to the human bone (17.7 GPa) in comparison
with Ti alloy (113 GPa) and Co–Cr alloy (240 GPa) which
reduces the stress shielding after implantation [125–127].
The bioactivity of porous PEEK was studied. [128] using
nine rabbits. Their findings suggest that the surface mod-
ification of PEEK may improve cell-material interaction. At
4 weeks post-surgery, an impermeable structure was
observed in both groups however, the bone tissue could not
be observed in the bare PEEK group. In Table 4 is possible
to have a general comparison of the different solutions
already discuss in this review.
Regardless of notable progress in bone tissue engineering
relatively few orthopedic designed have been used in clin-
ical [15]. The main limitation regarding current approaches
is insufficient vascularization and poor nutrient transport in
the scaffold resulting in the death of cells which leads to a
reduced osteointegration. Another limitation and although
there is a great demand in producing porous scaffolds is the
mechanical strength as it is heavily dependent on porosity
and geometry of the scaffold. Therefore the big challenge in
producing scaffolds for bone regeneration is in developing
an approach that allows cell penetration, nutrient, and
oxygen exchange and still is able to support load [15, 129].
In vitro assays allow the understanding of the fundamental
biological mechanism, the biological activity, toxicity and also
the evaluation of the cell response to the biomaterial. In this
sense, animal models are crucial in providing complementary
information on biological reactions such as inflammatory
reactions between scaffolds and bone and even to evaluate the
performance of the scaffold. a number of animal models, such
as rat/mouse, rabbit, sheep, goat, and pig have been used to
simulate human environment [130, 131]. Table 5 represents
the recent in vivo studies performed to test scaffolding bio-
materials for bone tissue applications.
Table 4 Comparison of the different solution for bone defect treatment
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5 Biodegradable coatings for scaffolds
Each biomaterial has its own advantages and disadvantages
as bone scaffold biomaterial which could be overcome by
combining different biomaterials. To improve the properties
of scaffolds for bone tissue applications, taking advantage
of the good mechanical properties of some materials and the
bioactivity of other, researchers have been coating them
with materials that mimic the natural bone surface
[132, 133]. There are key requirements for coated products
such as adequate stability of the coat in the biologic agent in
excipient coating matrix; optimized kinetics; ability to be
sterilized by conventional techniques [134].
A study performed in 1988 [135] used plasma-spray to
coated titanium implants with apatite and evaluated in vivo
in a canine model. The authors reported that apatite-coated
implants could bond as strong as the cortical bone itself.
Calcium phosphate-based materials such as HA, β-TCP and
biphasic calcium phosphate have a similar composition of
natural bone which allows them to directly bond to living
bone [136, 137]. HA (Ca5(PO4)3(OH)) is important calcium
phosphate since its chemical composition and structure are
very similar to the mineral component of natural bone. It
has exceptional characteristics such as bioactivity, bio-
compatibility and can achieve very high mechanical
strength. As a coating, it can provide to the scaffold
osteoconductivity that enhance the cell attachments and
proliferation [29, 138, 139]. β-TCP is a well-characterized
osteoconductive biomaterial that can be used for bone
regeneration applications.
In 1971, Hench et al. discovered that BG, a silicate glass-
based, was able to bond with the bone and soft tissues
[140]. 45S5 and 13–93 are two well-known bioactive
glasses. This material has an amazing ability to form an
interfacial bond with the host tissue; when implanted, they
induce the formation of a dense surface layer of hydro-
xycarbonate apatite (HCA), which is very similar to the
mineral component of bones and ensures a great adhesion.
BG is a silicate based and by varying the proportions of
sodium oxide, calcium oxide, and silicon dioxide, all range
of forms can be produced from soluble to non-resorbable.
They possess both osteointegrative and osteoconductive
properties [57, 136]. One limitation of the use of 45S5 glass
and other bioactive glasses is that the local biological
microenvironment is influenced by their degradation pro-
ducts [136]. Borate bioactive glasses presents properties that
allow cell proliferation and differentiation in vitro [141]. In
a study, where it was compared to the ability to repair bone
defects of both β-TCP and BG and conclude that BG had
better performance, [142]. They also observed that the
dissolution products of BG were capable of promoting
osteogenesis which can lead to the regeneration of the bone
defect. Although BG has good potential for regenerate bone
the concentration of boron released is still a concern. A
similar conclusion was reached in another study [143]. In
this study, it was developed and tested a 3D porous struc-
ture of Ti6Al4V coated with BG. The in vitro results
demonstrated cell attachment, proliferation, and differ-
entiation of human bone marrow stromal cells. The obtained
coating presented stability and interfacial adhesion.
Polysaccharide based tissue engineered periosteum
composed of heparin-coated chitosan nanofibers was stu-
died in terms of delivering growth factors, support adipose-
derived mesenchymal stem cells (ASCs) delivery and
improvement of the incorporation of the allograft in a
critical-sized mouse femoral defect [144]. Female mouse
received untreated allografts, allografts seeded with ASCs,
allografts modified with nanofibers, or allografts modified
with nanofibers and ASCs. They observed that the ASCs
were delivered, also FGF-2 and TGF-β1 were delivered
successfully. It was observed, after 6 weeks of implantation,
a non-significant increase in the bone callus volume.
There are various techniques to coat scaffold’s surface
such as: spin coating, which is one of the most popular
technique to obtain uniformly thin coatings [145]; sol–gel
process is being used to prepared bioactive glasses [146];
electrophoretic deposition (EPD) is gaining attention in the
biomedical field as it can achieve uniform coating in scaf-
folds with complex and porous shapes [147]; auto-catalytic
deposition [148]; dip coating [149]; spray deposition
[150, 151]; ion beam assisted deposition [152] and other
techniques.
Although the coatings studies were translated into
thousands of publications very few products have accom-
plished clinical implementation. It is crucial for scaffold’s
good performance its surface properties. The functionali-
zation of the scaffold’s surface with bioactive coatings is a
promising strategy, yet it presents limitations such as the
difficulty of achieving and uniform coat and interfacial
adhesion.
6 Conclusions and final remarks
The regeneration of bone defects is a complex problem.
Although there are numerous studies applying bone tissue
engineering to regenerate bone defects there still no opti-
mized approach due to high rates of complication and poor
functional outcomes. Several products have been proposed
like the use of coatings with a similar composition of the
bone to overcome the lack of osteointegration. However,
coatings need to present sufficient mechanical integrity and
surface adhesion to support the mechanical load. In order to
allow cell and vessels penetration for a proper bone for-
mation porous scaffolds have been proposed. Nevertheless,
the introduction of pores may lead to a decrease in
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mechanical properties. Growth factor delivery treatment
presents successful results in many studies but there have
been growing issues caused by the use of certain growth
factors, proper dosage, and combination. It is important to
optimize the scaffolds so they can match the mechanical
characteristic of bone. The majority of the strategies were
only tested in small animal models such as mice and also
testing in large animal models is important to properly
analyze the effects. Current scaffolds are not chemically or
patient-specific which makes them not ideal for many
clinical applications. This is a tremendous gap that should
be overcome in order to fasten their translation into clinics.
A great challenge is the production of a biomaterials scaf-
fold that replicates the highly porous structure of cancellous
bone while having high mechanical strength to provide
support in load-bearing defects.
In summary, the main challenges for bone regeneration
are to achieve proper mechanical properties to bear the load
of normal movements; have a scaffolds that allows vascu-
larization in order to obtain a fully mature bone, moreover,
the scaffold has to be heterogeneous as bone is not uniform
biologically and biomechanically; lastly the use of the
scaffolds should be easy to handle and a one-step procedure.
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